Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALAVEN vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Metastatic breast cancer in patients who have received at least two prior chemotherapy regimens including an anthracycline and a taxane,Unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Eribulin is primarily metabolized by CYP3A4 with minor contributions from other CYP isoforms. It undergoes minimal hepatic metabolism and is predominantly excreted unchanged in bile and feces.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 87-95% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 20–30% bound to plasma proteins.
Vd approximately 32-48 L/m² (approx. 0.9-1.4 L/kg, assuming 70 kg). Large Vd indicates extensive tissue distribution.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Only intravenous route available; no oral bioavailability data as it is not administered orally.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
For creatinine clearance 30-50 m L/min: 1.1 mg/m2 on days 1 and 8 of a 21-day cycle. For creatinine clearance <30 m L/min: not recommended.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh A: 1.1 mg/m2 on days 1 and 8 of a 21-day cycle. Child-Pugh B: 0.7 mg/m2 on days 1 and 8 of a 21-day cycle. Child-Pugh C: not recommended.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established in pediatric patients.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended; monitor for toxicity.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
No FDA boxed warning.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Neutropenia: monitor complete blood counts prior to each dose; dose reduce or delay as needed,Peripheral neuropathy: monitor for neuropathy, dose reduce or discontinue if severe,QT prolongation: monitor ECG in patients with heart failure, bradyarrhythmias, or electrolyte abnormalities,Embryo-fetal toxicity: can cause fetal harm, advise effective contraception
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to eribulin or any components of the formulation
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Avoid grapefruit and grapefruit juice as they may increase eribulin levels.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibitor) and animal studies, HALAVEN can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, eribulin was embryotoxic and fetotoxic at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. If used during pregnancy or if the patient becomes pregnant while receiving this drug, apprise the patient of the potential hazard to the fetus. Avoid use during the first trimester due to high risk of teratogenicity; use during second and third trimesters may cause fetal growth restriction and oligohydramnios.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
It is not known whether eribulin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from HALAVEN, advise women not to breastfeed during treatment and for at least 2 weeks after the last dose. No M/P ratio available.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No specific dosing adjustments for pregnancy have been established. Physiological changes during pregnancy (e.g., increased plasma volume, renal clearance) may alter eribulin pharmacokinetics, but no data exist. Use the standard dose of 1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle, with dose adjustments based on toxicity (e.g., neutropenia, thrombocytopenia, hepatic impairment) rather than pregnancy status.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Halaven (eribulin) is a nontaxane microtubule inhibitor used in metastatic breast cancer and liposarcoma. Monitor for neutropenia, peripheral neuropathy, and QT prolongation. Dose reduction required for moderate hepatic impairment (Child-Pugh B). Administer intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle. Antiemetic prophylaxis recommended.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
This drug can lower your white blood cell count, increasing infection risk. Report fever or chills immediately.,You may experience numbness, tingling, or weakness in your hands or feet; notify your doctor if these occur.,Halaven can cause fatigue, nausea, and hair loss; supportive care is available.,Avoid grapefruit and grapefruit juice during treatment due to potential interaction.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medication.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALAVEN vs CLADRIBINE, answered by our medical review team.
HALAVEN is a Antineoplastic Agent that works by Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALAVEN and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALAVEN is: 1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALAVEN and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALAVEN is classified as Category C. FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibitor) and animal studies, HALAVEN can cause fetal harm when administered to a pregnant woman. In animal. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.